#154645

ZR-75-1 estrogen independent breast cancer cell line panel (2)

Cat. #154645

ZR-75-1 estrogen independent breast cancer cell line panel (2)

Cat. #: 154645

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 10-12 weeks

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Institute: Erasmus University Medical Center (Erasmus MC)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: ZR-75-1 estrogen independent breast cancer cell line panel (2)
  • Tool sub type: Continuous
  • Parental cell: ZR-75-1
  • Organism: Human
  • Tissue: Breast
  • Disease: Cancer
  • Model: Cancer Model
  • Conditional: No
  • Description: Endocrine therapy of breast cancer has been applied widely and proven to be effective. However, in many instances endocrine treatments ultimately fail due to the development of an estrogen-independent therapy resistant phenotype. To elucidate the molecular mechanism underlying this endocrine therapy failure, the laboratory of Lambert Dorssers applied different genetic screens to identify the main genes conferring estrogen independence. Out of 15 candidate BCAR genes, several including BCAR1...
  • Production details: Full length cDNA of the relevant gene was introduced in the estrogen-dependent ZR-75-1 cell line by transfection with lipofectamine

Target Details

  • Target: BCAR1, BCAR3, AKT1, AKT2, BCAR4, GRB7, EGFR, HRAS, PDGFRA, PDGFRB, RAF1

Applications

  • Application notes: These cell lines are resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells. As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.

Handling

  • Format: Frozen
  • Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice

References

  • Godinho et al. 2011. J Cell Physiol. 226(7):1741-9. PMID: 21506106.
  • van Agthoven et al. 2010. Endocr Relat Cancer. 17(1):215-30. PMID: 19966015.
  • van Agthoven et al. 2009. Breast Cancer Res Treat. 114(1):23-30. PMID: 18351453.
  • Meijer et al. 2006. Mol Cancer Res. 4(6):379-86. PMID: 16778085.
  • Brinkman et al. 2000. J Natl Cancer Inst. 92(2):112-20. PMID: 10639512.
  • van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.
  • van Agthoven et al. 1992. Cancer Res. 52(18):5082-8. PMI...